|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Van Cutsem E, Nordlinger B, Adam R, Köhne
CH, et al: Towards a pan-European consensus on the treatment of
patients with colorectal liver metastases. Eur J Cancer.
42:2212–2221. 2006.PubMed/NCBI
|
|
3
|
Yoo PS, Lopez-Soler RI, Longo WE and Cha
CH: Liver resection for metastatic colorectal cancer in the age of
neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer.
6:202–207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Andre T, Boni C, Mounedji-Boudiaf L, et
al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment
for colon cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar
|
|
5
|
Sargent DJ, Wieand HS, Haller DG, et al:
Disease-free survival versus overall survival as a primary end
point for adjuvant colon cancer studies: individual patient data
from 20,898 patients on 18 randomized trials. J Clin Oncol.
23:8664–8670. 2005. View Article : Google Scholar
|
|
6
|
Cunningham D, Humblet Y, Siena S, et al:
Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Cutsem E, Kohne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
|
|
8
|
Bokemeyer C, Bondarenko I, Makhson A, et
al: Fluorouracil, leucovorin, and oxaliplatin with and without
cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lièvre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006.PubMed/NCBI
|
|
11
|
Lièvre A, Bachet JB, Boige V, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008.
|
|
12
|
Moroni M, Veronese S, Benvenuti S, et al:
Gene copy number for epidermal growth factor receptor (EGFR) and
clinical response to antiEGFR treatment in colorectal cancer: a
cohort study. Lancet Oncol. 6:279–286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Di Fiore F, Blanchard F, Charbonnier F, et
al: Clinical relevance of KRAS mutation detection in metastatic
colorectal cancer treated by Cetuximab plus chemotherapy. Br J
Cancer. 96:1166–1169. 2007.PubMed/NCBI
|
|
14
|
De Roock W, Piessevaux H, De Schutter J,
et al: KRAS wild-type state predicts survival and is associated to
early radiological response in metastatic colorectal cancer treated
with cetuximab. Ann Oncol. 19:508–515. 2008.PubMed/NCBI
|
|
15
|
Jhawer M, Goel S, Wilson AJ, et al: PIK3CA
mutation/PTEN expression status predicts response of colon cancer
cells to the epidermal growth factor receptor inhibitor cetuximab.
Cancer Res. 68:1953–1961. 2008. View Article : Google Scholar
|
|
16
|
Scartozzi M, Bearzi I, Pierantoni C, et
al: Nuclear factor-kB tumor expression predicts response and
survival in irinotecan-refractory metastatic colorectal cancer
treated with cetuximab-irinotecan therapy. J Clin Oncol.
25:3930–3935. 2007. View Article : Google Scholar
|
|
17
|
Perrone F, Lampis A, Orsenigo M, et al:
PI3KCA/PTEN deregulation contributes to impaired responses to
cetuximab in metastatic colorectal cancer patients. Ann Oncol.
20:84–90. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Loupakis F, Ruzzo A, Cremolini C, et al:
KRAS codon 61, 146 and BRAF mutations predict resistance to
cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type
metastatic colorectal cancer. Br J Cancer. 101:715–721. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amado RG, Wolf M, Peeters M, et al:
Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Di Fiore F, Charbonnier F, Lefebure B, et
al: Clinical interest of KRAS mutation detection in blood for
anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer.
99:551–552. 2008.PubMed/NCBI
|
|
21
|
Hoshino R, Chatani Y, Yamori T, et al:
Constitutive activation of the 41-/43-kDa mitogen-activated protein
kinase signaling pathway in human tumors. Oncogene. 18:813–822.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oliveira C, Velho S, Moutinho C, et al:
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma
progression. Oncogene. 26:158–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuen ST, Davies H, Chan TL, et al:
Similarity of the phenotypic patterns associated with BRAF and KRAS
mutations in colorectal neoplasia. Cancer Res. 62:6451–6455.
2002.PubMed/NCBI
|
|
24
|
Artale S, Sartore-Bianchi A, Veronese SM,
et al: Mutations of KRAS and BRAF in primary and matched metastatic
sites of colorectal cancer. J Clin Oncol. 26:4217–4219. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rajagopalan H, Bardelli A, Lengauer C, et
al: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.
Nature. 418:9342002. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Souglakos J, Philips J, Wang R, et al:
Prognostic and predictive value of common mutations for treatment
response and survival in patients with metastatic colorectal
cancer. Br J Cancer. 101:465–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nash GM, Gimbel M, Cohen AM, et al: KRAS
mutation and microsatellite instability: two genetic markers of
early tumor development that influence the prognosis of colorectal
cancer. Ann Surg Oncol. 17:416–424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lecomte T, Berger A, Zinzindohoué F, et
al: Detection of free-circulating tumor-associated DNA in plasma of
colorectal cancer patients and its association with prognosis. Int
J Cancer. 100:542–548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pathak AK, Bhutani M, Kumar S, et al:
Circulating cell-free DNA in plasma/serum of lung cancer patients
as a potential screening and prognostic tool. Clin Chem.
52:1833–1842. 2006.PubMed/NCBI
|
|
30
|
Tórtola S, Steinert R, Hantschick M, et
al: Discordance between K-ras mutations in bone marrow
micrometastases and the primary tumor in colorectal cancer. J Clin
Oncol. 19:2837–2843. 2001.PubMed/NCBI
|
|
31
|
Albanese I, Scibetta AG, Migliavacca M, et
al: Heterogeneity within and between primary colorectal carcinomas
and matched metastases as revealed by analysis of Ki-ras and p53
mutations. Biochem Biophys Res Commun. 325:784–791. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai H, Mao L, Wang HS, et al: Epidermal
growth factor receptor mutations in plasma DNA samples predict
tumor response in Chinese patients with stages IIIB to IV
non-small-cell lung cancer. J Clin Oncol. 27:2653–2659. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gow CH, Chang YL, Hsu YC, et al:
Comparison of epidermal growth factor receptor mutations between
primary and corresponding metastatic tumors in tyrosine kinase
inhibitor-naive non-small-cell lung cancer. Ann Oncol. 20:696–702.
2009. View Article : Google Scholar
|
|
34
|
Kalikaki A, Koutsopoulos A, Trypaki M, et
al: Comparison of EGFR and K-RAS gene status between primary
tumours and corresponding metastases in NSCLC. Br J Cancer.
99:923–929. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ryan BM, Lefort F, McManus R, et al: A
prospective study of circulating mutant KRAS2 in the serum of
patients with colorectal neoplasia: strong prognostic indicator in
postoperative follow up. Gut. 52:101–108. 2003. View Article : Google Scholar
|
|
36
|
Yen LC, Yeh YS, Chen CW, et al: Detection
of KRAS oncogene in peripheral blood as a predictor of the response
to cetuximab plus chemotherapy in patients with metastatic
colorectal cancer. Clin Cancer Res. 15:4508–4513. 2009. View Article : Google Scholar : PubMed/NCBI
|
